SCHEMBL722293

SCHEMBL722293

[CH2]OCc1cc(C)on1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722294 0.81
SCHEMBL1715595 0.79
SCHEMBL9971015 0.78 NPC1 (0.40)
Hydrochloric Acid SCHEMBL3170086 0.78 MAPT (0.39)
SCHEMBL4882325 0.76 CNR2 (0.39)
SCHEMBL12530515 0.76 CYP2D6 (0.42)
SCHEMBL16805014 0.76 CNR2 (0.39)
SCHEMBL27452820 0.75 MAPT (0.41)
SCHEMBL2608870 0.73 TRPM8 (0.39)
SCHEMBL20232092 0.73 MAPT (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598154-B2 Pyridyl-amine fused azadecalin modulators CORCEPT THERAPEUTICS, INC. (US) 2013-12-03 US claimed
EP-2609097-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS Corcept Therapeutics, Inc. (US) 2013-07-03 EP claimed
US-20120220565-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2012-08-30 US claimed
WO-2012027702-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2012-03-01 WO claimed
US-8598154-B2 Pyridyl-amine fused azadecalin modulators CORCEPT THERAPEUTICS, INC. (US) 2013-12-03 US disclosed
EP-2609097-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS Corcept Therapeutics, Inc. (US) 2013-07-03 EP disclosed
US-20120220565-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2012-08-30 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
WO-2012027702-A1 PYRIDYL-AMINE FUSED AZADECALIN MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2012-03-01 WO disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed